Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsSolid TumorsProtocol groupAggressive LymphomasNeuro-OncologyDiseaseMalignant MeningitisNHL, B-Cell Type, Diffuse Large CellPrimary Lymphoma of the CNSSubgroupLymphomatous MeningitisICD10C79.3C83.-C83.3C85.9MeSHLymphoma, Large B-Cell, DiffuseMeningeal CarcinomatosisSequenceSTUDY OPTIMAL, Arm F-ASTUDY OPTIMAL, Arm F-BSTUDY OPTIMAL, Arm LF-ASTUDY OPTIMAL, Arm LF-BSTUDY OPTIMAL, Arm LF-CSTUDY OPTIMAL, Arm LF-DChemotherapyChemo-substanceMethotrexateRituximabChemo-substanceMethotrexateRituximabChemo-substanceMethotrexateRituximabChemo-substanceMethotrexateRituximabNo. Substances12 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneDextrose 5%DimetindenFamotidineFolinic acidFurosemideGranisetronNaCl 0.9%ParacetamolPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceBalanced Crystalloid SolutionDexamethasoneDextrose 5%DimetindenFamotidineFolinic acidFurosemideGranisetronNaCl 0.9%ParacetamolPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceBalanced Crystalloid SolutionDexamethasoneDextrose 5%DimetindenFamotidineFolinic acidFurosemideGranisetronNaCl 0.9%ParacetamolPotassium chloridePrednisoloneSodium BicarbonateSupportive substanceBalanced Crystalloid SolutionDexamethasoneDextrose 5%DimetindenFamotidineFolinic acidFurosemideGranisetronNaCl 0.9%ParacetamolPotassium chloridePrednisoloneSodium BicarbonateNo. Substances3912Protocol classificationTherapy classificationalternativeStudy protocol, currentIntensityhigh doseStandard doseTherapy indicationFirst lineseveral possibleTherapy phaseTherapy intentioncurativepalliativeRisksEmetogenicity only studiesPublicationAuthorAbramson JPfreundschuh MRubenstein JDiseaseaggressive CD20+ B-NHL, 61-80 Jahre, Hochrisiko-Patienten, ECOG 0-1diffus großzelliges Non-Hodgkin-Lymphom, HochrisikoWiederkehrendes oder refraktäres ZNS Lymphom primär oder NHL, CD20+, PS über 50OriginCancer Center, Massachusetts General Hospital, BostonDivision of Hematology Oncology, University of California; Memorial Sloan-Kettering Cancer Center, New YorkDSHNHL 2009-1, OPTIMAL > 60Protocols in Revision 3 protocols foundProtocols under revision.Methotrexate 500/3000, CNS Prophylaxis, Malignant Meningitis (PID1001 V1.1)Rituximab 25, Malignant Meningitis (PID2571 V1.0)Study - OPTIMAL - Rituximab 375 / high dose Methotrexate 3000, diffuse large B-non-Hodgkin Lymphoma, CNS Prophylaxis (PID1133 V1.0)
